新型强效MDM2抑制剂BI-907828在体外抑制胶质母细胞瘤脑肿瘤干细胞并延长原位异种移植小鼠生存期
本研究在胶质母细胞瘤患者来源脑肿瘤干细胞中评估MDM2抑制剂BI-907828的体外与体内疗效。BI-907828在皮摩尔浓度下降低MDM2扩增及正常拷贝数TP53野生型细胞活力并诱导细胞死亡,单次50 mg/kg口服激活p53靶基因,长期每周或每两周给药耐受良好并改善原位异种移植小鼠生存。
要点
- BI-907828在皮摩尔浓度下降低MDM2扩增和正常拷贝数TP53野生型脑肿瘤干细胞活力并诱导细胞死亡。
- 单次50 mg/kg口服BI-907828在原位荷瘤SCID小鼠中强烈激活p53靶基因p21和MIC1。
- 长期每周或每两周给药耐受良好,单药及联合替莫唑胺均改善原位异种移植模型生存。
核心结论
- BI-907828为TP53野生型原发性脑肿瘤患者提供有前景的新治疗选择。
研究设计与样本
- 研究在胶质母细胞瘤患者来源脑肿瘤干细胞(BTSCs)中体外评估BI-907828,并在原位异种移植模型中进行体内评估。
主要发现
- BI-907828在皮摩尔浓度下降低MDM2扩增和正常拷贝数TP53野生型BTSC细胞系活力并诱导细胞死亡。
- 在TP53野生型而非TP53突变BTSCs中观察到p53活性恢复,包括强烈p21表达和凋亡诱导。
- shRNA介导的TP53敲低在野生型BTSCs中消除了BI-907828的作用,证实抑制剂特异性。
- 原位荷瘤SCID小鼠单次50 mg/kg口服BI-907828导致p53靶基因p21和MIC1强烈激活。
- 长期每周或每两周BI-907828治疗在原位BTSC异种移植模型中耐受良好,单药及联合替莫唑胺均改善生存,MDM2扩增模型呈剂量依赖性疗效。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The tumor suppressor TP53 (p53) is frequently mutated, and its downstream effectors inactivated in many cancers, including glioblastoma (GBM). In tumors with wild-type status, p53 function is frequently attenuated by alternate mechanisms including amplification and overexpression of its key negative regulator, MDM2. We investigated the efficacy of the MDM2 inhibitor, BI-907828, in GBM patient-derived brain tumor stem cells (BTSCs) with different amplification statuses of MDM2, in vitro and in orthotopic xenograft models. METHODS: In vitro growth inhibition and on-target efficacy of BI-907828 were assessed by cell viability, co-immunoprecipitation assays, and western blotting. In vivo efficacy of BI-907828 treatments was assessed with qPCR, immunohistochemistry, and in intracranial xenograft models. RESULTS: BI-907828 decreases viability and induces cell death at picomolar concentrations in both MDM2 amplified and normal copy number TP53 wild-type BTSC lines. Restoration of p53 activity, including robust p21 expression and apoptosis induction, was observed in TP53 wild-type but not in TP53 mutant BTSCs. shRNA-mediated knock-down of TP53 in wild-type BTSCs abrogated the effect of BI-907828, confirming the specificity of the inhibitor. Pharmacokinetic-pharmacodynamic studies in orthotopic tumor-bearing severe combined immunodeficiency (SCID) mice demonstrated that a single 50 mg/kg p.o. dose of BI-907828 resulted in strong activation of p53 target genes p21 and MIC1. Long-term weekly or bi-weekly treatment with BI-907828 in orthotopic BTSC xenograft models was well-tolerated and improved survival both as a single-agent and in combination with temozolomide, with dose-dependent efficacy observed in the MDM2 amplified model. CONCLUSIONS: BI-907828 provides a promising new therapeutic option for patients with TP53 wild-type primary brain tumors.
引用
- Hao X, Bahia RK, Cseh O, et al. BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models. Neuro Oncol. 2023. PMID: 36521007. doi:10.1093/neuonc/noac271
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。